Loading...

Assertio Therapeutics

Nasdaq:ASRT
Snowflake Description

Fair value with imperfect balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ASRT
Nasdaq
$219M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Assertio Therapeutics, Inc., a specialty pharmaceutical company, provides medicines in neurology, orphan, and specialty areas in the United States. The last earnings update was 14 days ago. More info.


Add to Portfolio Compare Print
  • Assertio Therapeutics has significant price volatility in the past 3 months.
ASRT Share Price and Events
7 Day Returns
-4.2%
NasdaqGS:ASRT
1.1%
US Pharmaceuticals
0.2%
US Market
1 Year Returns
-49.6%
NasdaqGS:ASRT
9.6%
US Pharmaceuticals
2.9%
US Market
ASRT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Assertio Therapeutics (ASRT) -4.2% -22% -20.2% -49.6% -83% -71.3%
US Pharmaceuticals 1.1% 2.5% -1.2% 9.6% 9.5% 18.2%
US Market 0.2% -1.6% 2.4% 2.9% 36.1% 41%
1 Year Return vs Industry and Market
  • ASRT underperformed the Pharmaceuticals industry which returned 9.6% over the past year.
  • ASRT underperformed the Market in United States of America which returned 2.9% over the past year.
Price Volatility
ASRT
Industry
5yr Volatility vs Market

ASRT Value

 Is Assertio Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Assertio Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Assertio Therapeutics.

NasdaqGS:ASRT Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 12.4%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGS:ASRT
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.64
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.643 (1 + (1- 21%) (252.31%))
1.619
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.62
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.619 * 5.96%)
12.38%

Discounted Cash Flow Calculation for NasdaqGS:ASRT using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Assertio Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGS:ASRT DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 12.38%)
2019 139.33 Est @ 11.74% 123.98
2020 151.92 Est @ 9.03% 120.29
2021 162.77 Est @ 7.14% 114.68
2022 172.24 Est @ 5.82% 107.98
2023 180.67 Est @ 4.89% 100.79
2024 188.33 Est @ 4.24% 93.49
2025 195.47 Est @ 3.79% 86.34
2026 202.26 Est @ 3.47% 79.49
2027 208.83 Est @ 3.25% 73.03
2028 215.29 Est @ 3.09% 67.00
Present value of next 10 years cash flows $967.06
NasdaqGS:ASRT DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $215.29 × (1 + 2.73%) ÷ (12.38% – 2.73%)
$2,291.43
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $2,291.43 ÷ (1 + 12.38%)10
$713.09
NasdaqGS:ASRT Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $967.06 + $713.09
$1,680.15
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,680.15 / 64.41
$26.09
NasdaqGS:ASRT Discount to Share Price
Calculation Result
Value per share (USD) From above. $26.09
Current discount Discount to share price of $3.40
= -1 x ($3.40 - $26.09) / $26.09
87%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Assertio Therapeutics is available for.
Intrinsic value
>50%
Share price is $3.4 vs Future cash flow value of $26.09
Current Discount Checks
For Assertio Therapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Assertio Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Assertio Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Assertio Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Assertio Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:ASRT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-0.18
NasdaqGS:ASRT Share Price ** NasdaqGS (2019-05-23) in USD $3.4
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 27 Publicly-Listed Pharmaceuticals Companies 21.05x
United States of America Market PE Ratio Median Figure of 3,085 Publicly-Listed Companies 17.79x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Assertio Therapeutics.

NasdaqGS:ASRT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:ASRT Share Price ÷ EPS (both in USD)

= 3.4 ÷ -0.18

-19.39x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Assertio Therapeutics is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Assertio Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Assertio Therapeutics's expected growth come at a high price?
Raw Data
NasdaqGS:ASRT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -19.39x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
-30%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.67x
United States of America Market PEG Ratio Median Figure of 2,123 Publicly-Listed Companies 1.54x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Assertio Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Assertio Therapeutics's assets?
Raw Data
NasdaqGS:ASRT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $3.24
NasdaqGS:ASRT Share Price * NasdaqGS (2019-05-23) in USD $3.4
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 179 Publicly-Listed Pharmaceuticals Companies 3.23x
United States of America Market PB Ratio Median Figure of 5,201 Publicly-Listed Companies 1.84x
NasdaqGS:ASRT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:ASRT Share Price ÷ Book Value per Share (both in USD)

= 3.4 ÷ 3.24

1.05x

* Primary Listing of Assertio Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Assertio Therapeutics is good value based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Assertio Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Assertio Therapeutics has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ASRT Future Performance

 How is Assertio Therapeutics expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-30%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Assertio Therapeutics expected to grow at an attractive rate?
  • Unable to compare Assertio Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Assertio Therapeutics's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Assertio Therapeutics's revenue growth is positive but not above the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:ASRT Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:ASRT Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts -30%
NasdaqGS:ASRT Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 1.3%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 14.8%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.7%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:ASRT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:ASRT Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 246 2
2022-12-31 239 2
2021-12-31 265 4
2020-12-31 243 84 -33 5
2019-12-31 235 30 -59 5
NasdaqGS:ASRT Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 241 127 -11
2018-12-31 312 72 37
2018-09-30 364 84 28
2018-06-30 381 10 -36
2018-03-31 419 19 -42
2017-12-31 381 62 -102
2017-09-30 410 76 -114
2017-06-30 425 96 -111
2017-03-31 442 103 -95
2016-12-31 456 71 -89
2016-09-30 443 88 -75
2016-06-30 437 120 -74

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Assertio Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Assertio Therapeutics's revenue is expected to grow by 1.3% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:ASRT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Assertio Therapeutics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:ASRT Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 -0.51 -0.51 -0.51 1.00
2019-12-31 -0.92 -0.92 -0.92 1.00
NasdaqGS:ASRT Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -0.18
2018-12-31 0.58
2018-09-30 0.44
2018-06-30 -0.57
2018-03-31 -0.67
2017-12-31 -1.63
2017-09-30 -1.82
2017-06-30 -1.79
2017-03-31 -1.53
2016-12-31 -1.45
2016-09-30 -1.23
2016-06-30 -1.22

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Assertio Therapeutics is expected to make outstanding use of shareholders’ funds in the future (Return on Equity greater than 40%).
X
Future performance checks
We assess Assertio Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Assertio Therapeutics has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ASRT Past Performance

  How has Assertio Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Assertio Therapeutics's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Assertio Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Assertio Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Assertio Therapeutics's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Assertio Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Assertio Therapeutics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:ASRT Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 241.30 -11.22 115.50 8.31
2018-12-31 311.77 36.91 119.73 8.04
2018-09-30 363.58 27.94 142.89 7.09
2018-06-30 381.50 -36.32 159.63 6.73
2018-03-31 418.68 -41.93 179.16 10.16
2017-12-31 380.72 -102.50 203.40 13.72
2017-09-30 410.23 -113.76 203.30 21.61
2017-06-30 425.34 -110.66 204.53 30.26
2017-03-31 441.56 -94.54 205.58 31.77
2016-12-31 455.90 -88.72 204.62 32.63
2016-09-30 443.16 -75.02 194.10 29.82
2016-06-30 437.49 -73.91 191.67 24.03
2016-03-31 415.31 -85.02 196.88 21.63
2015-12-31 342.74 -75.74 178.87 17.54
2015-09-30 426.17 49.55 169.98 13.23
2015-06-30 372.79 67.79 147.99 10.25
2015-03-31 346.02 102.19 123.15 6.93
2014-12-31 390.36 131.76 121.13 7.12
2014-09-30 236.37 78.94 119.44 7.11
2014-06-30 222.35 79.00 118.74 6.80
2014-03-31 184.58 66.73 111.53 6.82
2013-12-31 134.21 43.31 104.98 8.07
2013-09-30 120.19 -2.19 101.73 9.23
2013-06-30 116.01 -10.20 102.18 13.17
2013-03-31 100.16 -26.46 101.84 15.28
2012-12-31 90.82 -29.78 97.65 15.46
2012-09-30 76.36 -39.91 95.16 15.06
2012-06-30 59.60 -46.99 89.80 13.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Assertio Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • Assertio Therapeutics used its assets less efficiently than the US Pharmaceuticals industry average last year based on Return on Assets.
  • It is difficult to establish if Assertio Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Assertio Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Assertio Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ASRT Health

 How is Assertio Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Assertio Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Assertio Therapeutics's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Assertio Therapeutics's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Assertio Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Assertio Therapeutics Company Filings, last reported 1 month ago.

NasdaqGS:ASRT Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 208.55 552.50 109.69
2018-12-31 220.34 566.11 110.95
2018-09-30 242.41 585.53 121.90
2018-06-30 191.21 580.04 57.23
2018-03-31 206.09 632.15 101.69
2017-12-31 169.51 626.73 128.09
2017-09-30 198.65 634.39 113.46
2017-06-30 211.40 629.55 116.80
2017-03-31 230.22 723.43 194.51
2016-12-31 250.79 718.78 177.42
2016-09-30 290.73 714.19 135.91
2016-06-30 297.10 709.73 117.75
2016-03-31 299.74 804.56 192.32
2015-12-31 315.06 800.33 209.77
2015-09-30 341.66 802.61 172.48
2015-06-30 346.10 798.83 118.00
2015-03-31 360.07 233.06 61.09
2014-12-31 364.45 229.89 559.44
2014-09-30 263.47 226.77 553.47
2014-06-30 179.33 0.00 218.04
2014-03-31 160.35 0.00 208.49
2013-12-31 137.42 0.00 271.94
2013-09-30 92.21 0.00 80.58
2013-06-30 82.93 0.00 69.55
2013-03-31 80.26 0.00 66.35
2012-12-31 83.94 0.00 66.81
2012-09-30 85.65 0.00 79.91
2012-06-30 85.40 0.00 72.21
  • Assertio Therapeutics's level of debt (264.9%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 264.9% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Whilst loss making Assertio Therapeutics has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Whilst loss making Assertio Therapeutics has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 9.4% per year.
X
Financial health checks
We assess Assertio Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Assertio Therapeutics has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ASRT Dividends

 What is Assertio Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Assertio Therapeutics dividends. Estimated to be 0% next year.
If you bought $2,000 of Assertio Therapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Assertio Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Assertio Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:ASRT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2005 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:ASRT Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Assertio Therapeutics has not reported any payouts.
  • Unable to verify if Assertio Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Assertio Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Assertio Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Assertio Therapeutics's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Assertio Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Assertio Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Assertio Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ASRT Management

 What is the CEO of Assertio Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Art Higgins
COMPENSATION $4,784,027
AGE 62
TENURE AS CEO 2.2 years
CEO Bio

Mr. Arthur Joseph Higgins, also known as Art, has been Chief Executive Officer, President and Director of Depomed, Inc. since March 28, 2017. Mr. Higgins founded Ascendancy Healthcare, Inc. in 2011 and serves as its Executive Chairman. He serves as Senior Advisor at Blackstone Healthcare Partners, the dedicated healthcare team of The Blackstone Group, where he focuses on product-based healthcare acquisitions since June 2010. Mr. Higgins is a highly respected executive with over 35 years’ experience in the pharmaceutical and healthcare industry. Mr. Higgins served as Senior Advisor at The Blackstone Group, L.P. He has extensive leadership experience in the global healthcare market. He has gained deep knowledge of the healthcare market and the strategies for developing and marketing products in this highly regulated area. He served as the Chief Executive Officer of Bayer HealthCare AG from January 1, 2006 to April 30, 2010. He served as the Chairman of the Board of Management and Member of Management Board at Bayer HealthCare AG. He served as the Chairman and Member of Management Board of Bayer Pharma AG from September 14, 2006 to September 1, 2008 and its Chief Executive Officer until September 1, 2008. Prior to joining Bayer HealthCare in 2004, he served as the Chief Executive Officer and President of Enzon, Inc. (Enzon Pharmaceuticals Inc.) from May 31, 2001 to 2004. He also held various other positions at Abbott Laboratories, including President of Pharmaceutical Operations, Vice President of Pacific, Asia and Africa Operations and Vice President of International Business Development. He started his career in 1978 in Britain with Bristol-Myers. He subsequently worked for Sandoz from 1979 to 1984 and Fisons from 1984 to 1987 before moving to Abbott Laboratories in the USA from 1987 to 2001, where he held positions of increasing responsibility in the international and domestic divisions, including a two-year posting in Germany. He served as the President of the Pharmaceutical Products Division in Chicago at Abbott Laboratories from 1998 to 2001. In this position, he was in charge of Abbott's pharmaceuticals business in the U.S. with responsibility for global pharmaceutical research and development. He served as the Chairman of Bayer HealthCare AG. He served as the Chairman of Enzon Pharmaceuticals Inc. from December 3, 2001 to September 29, 2004. He has been an Independent Director of Zimmer Biomet Holdings, Inc. since February 12, 2007 and Eco lab Inc. since May 6, 2010. Mr. Higgins serves as a Director of NantPharma, LLC, NantWorks LLC and MPD Acquisition LLC. He served as a Director of Zenith Epigenetics Corp. until February 11, 2014. He has been an Independent Director of Ecolab Inc. since May 6, 2010. He served as an Independent Director of Endo International plc since February 28, 2014 until March 31, 2017. He served as a Director of Endo Health Solutions Inc. from December 2013 to February 2014. He served as Director at Enzon Pharmaceuticals Inc. from May 31, 2001 to December 7, 2004. He served as a Director of Catalent Pharma Solutions, Inc. since August 1, 2010. He served as a Director at Resverlogix Corp. from February 1, 2010 to February 2014. He has been a Member of Schering since September 14, 2006. He was the Chairman of the Biotechnology Council of New Jersey. He is a past member of the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA), of the Council of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and President of the European Federation of Pharmaceutical Industries and Associations (EFPIA). Mr. Higgins holds a Bachelor of Science degree in Biochemistry from Strathclyde University, Glasgow, Scotland in 1978.

CEO Compensation
  • Art's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Art's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Assertio Therapeutics management team in years:

1.2
Average Tenure
56
Average Age
  • The average tenure for the Assertio Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Art Higgins

TITLE
CEO, President & Director
COMPENSATION
$5M
AGE
62
TENURE
2.2 yrs

Dan Peisert

TITLE
CFO, Principal Accounting Officer & Senior VP
COMPENSATION
$955K
AGE
44
TENURE
0.4 yrs

Stan Bukofzer

TITLE
Senior VP and Chief Scientific & Technical Officer
COMPENSATION
$2M
AGE
62
TENURE
0.2 yrs

Sharon Larkin

TITLE
Senior Vice President of Human Resources & Administration
AGE
54
TENURE
1.3 yrs

John Thomas

TITLE
Senior Vice President of IR & Corporate Communications
AGE
54
TENURE
1.1 yrs

Amar Murugan

TITLE
Senior VP

Mark Booth

TITLE
Senior VP & Chief Commercial Officer
AGE
58
TENURE
1.5 yrs
Board of Directors Tenure

Average tenure and age of the Assertio Therapeutics board of directors in years:

2.2
Average Tenure
59.5
Average Age
  • The average tenure for the Assertio Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Jim Fogarty

TITLE
Chairman of the Board
COMPENSATION
$288K
AGE
50
TENURE
2.2 yrs

Art Higgins

TITLE
CEO, President & Director
COMPENSATION
$5M
AGE
62
TENURE
2.2 yrs

Jim Tyree

TITLE
Director
COMPENSATION
$273K
AGE
65
TENURE
2.6 yrs

Bill McKee

TITLE
Director
COMPENSATION
$276K
AGE
56
TENURE
2.2 yrs

Peter Staple

TITLE
Independent Director
COMPENSATION
$275K
AGE
66
TENURE
15.5 yrs

Karen Dawes

TITLE
Independent Director
COMPENSATION
$264K
AGE
66
TENURE
11.1 yrs

Heather Mason

TITLE
Director
AGE
57
TENURE
0.3 yrs

James Galeota

TITLE
Director
AGE
51
TENURE
0.2 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Assertio Therapeutics insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
09. May 19 Sell William McKee Individual 09. May 19 09. May 19 -12,500 $4.70 $-58,699
18. Mar 19 Buy Arthur Higgins Individual 14. Mar 19 14. Mar 19 10,000 $4.17 $41,700
18. Mar 19 Buy Stanley Bukofzer Individual 14. Mar 19 14. Mar 19 5,000 $4.13 $20,658
18. Mar 19 Buy Daniel Peisert Individual 14. Mar 19 14. Mar 19 6,000 $4.18 $25,069
X
Management checks
We assess Assertio Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Assertio Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ASRT News

Simply Wall St News

Before You Buy Assertio Therapeutics, Inc. (NASDAQ:ASRT), Consider Its Volatility

Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … Before we go on, it's worth noting that Warren Buffett pointed out in his 2014 letter to shareholders that 'volatility is far from synonymous with risk.' Having said that, beta can still be rather useful. … A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.

Simply Wall St -

If You Had Bought Assertio Therapeutics Stock Three Years Ago, You'd Be Sitting On A 73% Loss, Today

(NASDAQ:ASRT); the share price is down a whopping 73% in the last three years. … And over the last year the share price fell 39%, so we doubt many shareholders are delighted. … Shareholders have had an even rougher run lately, with the share price down 17% in the last 90 days.

Simply Wall St -

Does Assertio Therapeutics, Inc. (NASDAQ:ASRT) Have A High Beta?

(NASDAQ:ASRT), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.

Simply Wall St -

Is Assertio Therapeutics Inc's (NASDAQ:ASRT) 12% ROE Strong Compared To Its Industry?

Assertio Therapeutics has a ROE of 12%, based on the last twelve months. … That means that for every $1 worth of shareholders' equity, it generated $0.12 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Is There An Opportunity With Assertio Therapeutics Inc's (NASDAQ:ASRT) 32.51% Undervaluation?

by estimating the company's future cash flows and discounting them to their present value. … Discounted Cash Flows (DCF). … If you are reading this and its not October 2018 then I highly recommend you check out the latest calculation for Assertio Therapeutics by following the link below

Simply Wall St -

ASRT Company Info

Description

Assertio Therapeutics, Inc., a specialty pharmaceutical company, provides medicines in neurology, orphan, and specialty areas in the United States. The company offers Gralise (gabapentin), a once daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug for the acute treatment of migraine attacks; and Zipsor (diclofenac potassium liquid filled capsules), a non-steroidal anti-inflammatory drug for treating mild to moderate acute pain. It also provides NUCYNTA ER (tapentadol extended release tablet), a product for the management of pain severe enough to require daily, around-the-clock, and long term opioid treatment, including neuropathic pain related to diabetic peripheral neuropathy in adults; and NUCYNTA IR (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, the company offers long-acting cosyntropin, an alcohol-free formulation of synthetic adrenocorticotropic hormone. Assertio Therapeutics, Inc. has a collaboration and license agreement with Ironwood Pharmaceuticals, Inc. The company was formerly known as Depomed Inc. and changed its name to Assertio Therapeutics, Inc. in August 2018. Assertio Therapeutics, Inc. was founded in 1995 and is headquartered in Lake Forest, Illinois.

Details
Name: Assertio Therapeutics, Inc.
ASRT
Exchange: NasdaqGS
Founded: 1995
$218,977,550
64,405,162
Website: http://www.assertiotx.com
Address: Assertio Therapeutics, Inc.
100 South Saunders Road,
Suite 300,
Lake Forest,
Illinois, 60045,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS ASRT Common Stock Nasdaq Global Select US USD 02. Dec 1997
DB DPOA Common Stock Deutsche Boerse AG DE EUR 02. Dec 1997
Number of employees
Current staff
Staff numbers
116
Assertio Therapeutics employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/23 23:35
End of day share price update: 2019/05/23 00:00
Last estimates confirmation: 2019/05/16
Last earnings filing: 2019/05/09
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.